Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Arcturus Therapeutics to post earnings of ($1.17) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. The firm had revenue of $33.99 million for the quarter, compared to analyst estimates of $64.14 million. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Arcturus Therapeutics Price Performance
Shares of ARCT opened at $27.32 on Tuesday. The firm has a fifty day moving average price of $32.47 and a 200 day moving average price of $30.07. Arcturus Therapeutics has a 1-year low of $17.52 and a 1-year high of $43.81.
Wall Street Analyst Weigh In
View Our Latest Research Report on Arcturus Therapeutics
Insider Buying and Selling at Arcturus Therapeutics
In other news, COO Pad Chivukula sold 17,435 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the transaction, the chief operating officer now owns 473,448 shares in the company, valued at approximately $16,580,148.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.80% of the stock is owned by corporate insiders.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Further Reading
- Five stocks we like better than Arcturus Therapeutics
- About the Markup Calculator
- Lemonade Squeezes as Breakeven Date Gets Pulled Closer
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Tech Earnings Insights: Where Opportunity Meets Uncertainty
- How to Effectively Use the MarketBeat Ratings Screener
- 3 CEO-Led Turnaround Stocks You Can Still Buy
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.